Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Buys $98,000.00 in Stock

Eyenovia, Inc. (NASDAQ:EYEN) major shareholder Stuart M. Grant bought 100,000 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were acquired at an average cost of $0.98 per share, with a total value of $98,000.00. Following the purchase, the insider now directly owns 5,430,715 shares of the company’s stock, valued at approximately $5,322,100.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Eyenovia Price Performance

Shares of EYEN opened at $0.99 on Friday. The company has a market capitalization of $46.73 million, a P/E ratio of -1.47 and a beta of 1.72. The company has a quick ratio of 2.16, a current ratio of 2.17 and a debt-to-equity ratio of 1.00. The firm has a 50 day moving average of $1.66 and a 200 day moving average of $1.59. Eyenovia, Inc. has a twelve month low of $0.92 and a twelve month high of $5.85.

Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). During the same quarter in the prior year, the company posted ($0.17) EPS. As a group, equities research analysts anticipate that Eyenovia, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eyenovia

Several institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC increased its position in shares of Eyenovia by 41.8% during the fourth quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock valued at $9,106,000 after acquiring an additional 1,290,979 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Eyenovia by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,429,577 shares of the company’s stock worth $2,974,000 after purchasing an additional 61,732 shares during the last quarter. BlackRock Inc. boosted its holdings in Eyenovia by 1,704.3% in the second quarter. BlackRock Inc. now owns 1,334,953 shares of the company’s stock worth $3,164,000 after purchasing an additional 1,260,966 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Eyenovia by 113.6% in the second quarter. Geode Capital Management LLC now owns 555,479 shares of the company’s stock worth $1,316,000 after purchasing an additional 295,412 shares during the last quarter. Finally, State Street Corp boosted its holdings in Eyenovia by 433.5% in the second quarter. State Street Corp now owns 442,382 shares of the company’s stock worth $1,048,000 after purchasing an additional 359,465 shares during the last quarter. Institutional investors own 25.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research note on Tuesday, March 19th.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.